Hearing explores how drug companies stifle innovation, prioritize profits
The House Energy and Commerce Subcommittee on Consumer Protection and Commerce today held a hearing to examine how pharmaceutical companies are putting “profits over consumers,” highlighting how profits made from drug sales are concentrated around only a few drugs with no competition. “The bottom line is this: drug manufacturers are gaming the system to make more money at consumers’ expense,” said Chairwoman Jan Schakowsky, D-Ill. “And that has to stop.” Witnesses for the hearing were from Rutgers Institute for Information Policy and Law, Emory University School of Law, the Association for Accessible Medicines, and Patients for Affordable Drugs.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services Sept. 30 finalized its Global Benchmark for Efficient Drug Pricing Model, also known as the GLOBE Model. The…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 28 that it projects declines in average premiums for Medicare Advantage and Part D in 2027.…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 18 that all 50 states, Washington, D.C., and Puerto Rico have applied to participate in its…
Headline
The Trump administration announced Aug. 31 agreements with nine additional pharmaceutical manufacturers aimed at lowering prescription drug prices through a…
Headline
The AHA Aug. 17 provided comments to the Centers for Medicare & Medicaid Services on its proposed rule to codify in regulation the Medicare Drug Price…
Headline
The Centers for Medicare & Medicaid Services July 16 released draft guidance for the 2028 cycle of negotiations under the Medicare Drug Price Negotiation…